|
|
Regeneron Pharmaceuticals Inc (REGN) |
|
|
|
| |
REGN's Net Income Growth by Quarter and Year
Regeneron Pharmaceuticals Inc 's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| REGN Net Income (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
1,197.10
|
2,229.00
|
1,149.20
|
792.00
|
| III Quarter |
September |
1,315.70
|
1,632.20
|
842.10
|
669.60
|
| II Quarter |
June |
852.10
|
3,098.90
|
897.30
|
193.10
|
| I Quarter |
March |
973.50
|
1,115.20
|
624.60
|
461.10
|
| FY |
|
4,338.40
|
8,075.30
|
3,513.20
|
2,115.80
|
| REGN Net Income forth quarter 2022 Y/Y Growth Comment |
Regeneron Pharmaceuticals Inc reported drop in Net Income in the forth quarter 2022 by -46.29% to $ 1,197.10 millions, from the same quarter in 2021.
The fall in the forth quarter 2022 Regeneron Pharmaceuticals Inc 's Net Income compares unfavorably to the Company's average Net Income growth of 8.64%.
Looking into forth quarter 2022 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income growth. While Regeneron Pharmaceuticals Inc ' s Net Income meltdown of -46.29% ranks overall at the positon no. 1100 in the forth quarter 2022.
|
| REGN Net Income ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
-46.29 % |
93.96 % |
45.1 % |
-19.47 % |
| III Quarter |
September |
-19.39 % |
93.82 % |
25.76 % |
12.6 % |
| II Quarter |
June |
-72.5 % |
245.36 % |
364.68 % |
-64.98 % |
| I Quarter |
March |
-12.71 % |
78.55 % |
35.46 % |
-3.53 % |
| FY |
|
-46.28 % |
129.86 % |
66.05 % |
-18.86 % |
REGN Net Income (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
-9.01 % |
36.56 % |
36.47 % |
18.28 % |
| III Quarter |
September |
54.41 % |
-47.33 % |
-6.15 % |
246.76 % |
| II Quarter |
June |
-12.47 % |
177.88 % |
43.66 % |
-58.12 % |
| I Quarter |
March |
-56.33 % |
-2.96 % |
-21.14 % |
-53.11 % |
| FY (Year on Year) |
|
-46.28 % |
129.86 % |
66.05 % |
-18.86 % |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 54.99 % |
8.64 % |
-57.58 % |
| (Jun 30 2021) |
|
(March 31, 2014) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 54.99 % |
8.64 % |
-57.58 % |
| (Jun 30 2021) |
|
(March 31, 2014) |
|
| Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Regeneron Pharmaceuticals Inc 's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 1453.73 % |
78.01 % |
-97.02 % |
| (Mar 31 2014) |
|
|
| REGN's IV. Quarter Q/Q Net Income Comment |
In the IV. Quarter 2022 Regeneron Pharmaceuticals Inc reported drop in Net Income sequentially by -9.01% to $ 1,197.10 millions, from $ 1,315.70 millions released a quarter before.
Although periodic influence commonly energize IV. Quarter 2022 performance, that simply was not enough to recover Regeneron Pharmaceuticals Inc 's IV. Quarter outcome, Thomas Evans, Major Pharmaceutical Preparations industry expert wrote and continued that average sequential Net Income growth is at 78.01% for Regeneron Pharmaceuticals Inc .
Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Net Income quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 241. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 1453.73 % |
78.01 % |
-97.02 % |
| (Mar 31 2014) |
|
|
| REGN's IV. Quarter Q/Q Net Income Comment |
In the IV. Quarter 2022 Regeneron Pharmaceuticals Inc disclosed drop in Net Income sequentially by -9.01% to $ 1,197.10 millions, from $ 1,315.70 millions achived in the previous reporting period.
Those periodic influence which usually energize IV. Quarter 2022 results, could not rescue the IV. Quarter for the Regeneron Pharmaceuticals Inc , Thomas Evans, Major Pharmaceutical Preparations industry expert pointed out.
Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Net Income quarter on quarter growth. While Regeneron Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 241. |
|
Regeneron Pharmaceuticals Inc 's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
| Cumulative Net Income 12 Months Ending |
$ 4,338.40 |
$ 5,370.30 |
$ 5,686.80 |
$ 7,933.60 |
$ 8,075.30 |
| Y / Y Net Income Growth (TTM) |
-46.28 % |
-23.23 % |
-8.36 % |
98.15 % |
129.86 % |
| Year on Year Net Income Growth Overall
Ranking |
# 1041 |
# 1345 |
# 348 |
# 95 |
# 468 |
| Seqeuential Net Income Change (TTM) |
-19.21 % |
-5.57 % |
-28.32 % |
-1.75 % |
15.44 % |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 1100 |
# 2286 |
# 1523 |
# 194 |
# 871 |
| Cumulative Net Income growth
Comment |
Regeneron Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -46.28% year on year, at Dec 31 2022 compare to the -23.23% decrease at Sep 30 2022. If the Regeneron Pharmaceuticals Inc 's fiscal year would end at Dec 31 2022, annual Net Income would be $4,338 millions.
In the Healthcare sector 67 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1041, from total ranking in previous quarter at 1345. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
54.99 % |
8.64 % |
-57.58 % |
|
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
144.2 % |
41.09 % |
-72.81 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 24 |
| Sector |
# 80 |
| S&P 500 |
# 1100 |
|
| Cumulative Net Income growth
Comment |
Regeneron Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -46.28% year on year, at Dec 31 2022 compare to the -23.23% decrease at Sep 30 2022. If the Regeneron Pharmaceuticals Inc 's fiscal year would end at Dec 31 2022, annual Net Income would be $4,338 millions.
In the Healthcare sector 67 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 1041, from total ranking in previous quarter at 1345. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
54.99 % |
8.64 % |
-57.58 % |
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
144.2 % |
41.09 % |
-72.81 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 24 |
| Sector |
# 80 |
| S&P 500 |
# 1100 |
|
